Oncology Institute (NASDAQ:TOI) reported second-quarter revenue growth, positive adjusted EBITDA and an expanded pipeline of value-based oncology contracts as the company announced it has rebranded as Starling Oncology. Get alerts:Chief Executive Officer Dan Virnich said the new name reflects the company’s evolution into a national value-based oncology provider. The growth was driven largely by Specialty Pharmacy revenue, which increased 57.6% year over year to $98.6 million and represented 61.1% of total revenue. Patient Services revenue, including capitated and fee-for-service arrangements, rose 5.3% to $58.8 million, accounting for 36.5% of total revenue. About Oncology Institute (NASDAQ:TOI)The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States.